Drug Approval | November 02, 2024
USFDA inspection of Shilpa Medicare Unit VI at Bengaluru
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
We now rank 3rd in pharmaceutical production by volume and 14th by value
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
The inspection conducted by EDQM at its Visakhapatnam facility
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
Subscribe To Our Newsletter & Stay Updated
